New Trial for Celyad’s CAR T-cell Therapy in Ovarian, Other Cancers to Start in Belgium

New Trial for Celyad’s CAR T-cell Therapy in Ovarian, Other Cancers to Start in Belgium
Celyad’s new trial evaluating the effectiveness and safety of its drug candidate NKR-2 (a CAR T-cell therapy) in seven cancer types, including ovarian cancer, has been approved to start in Belgium. CAR T-cells are immune cells isolated from each patient that are genetically modified to gain a better capacity to identify and kill cancer cells based

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *